Thalassemia (Beta & Alpha)

Thalassemia is a group of inherited hemoglobin disorders caused by mutations in the genes that encode the globin chains of hemoglobin — the protein that carries oxygen in red blood cells. When globin chain production is reduced or absent, red blood cells become small, fragile, and short-lived, causing chronic anemia. Unlike acquired blood disorders such as leukemia, thalassemia is present from birth as a genetic condition. Unlike iron deficiency anemia, thalassemia does not respond to iron supplementation — in fact, iron is often dangerous in thalassemia because the body already accumulates excess iron from ineffective erythropoiesis and (in TDT) from transfusions. The spectrum of thalassemia ranges from completely asymptomatic carrier status to severe transfusion-dependent disease requiring lifelong treatment or curative intervention.

Beta-thalassemia is caused by mutations in the HBB gene on chromosome 11, which encodes the beta-globin chain of hemoglobin. It ranges from mild (beta-thalassemia trait — asymptomatic) to moderate (beta-thalassemia intermedia) to severe (beta-thalassemia major/TDT — requiring lifelong transfusions). Alpha-thalassemia is caused by deletions in the HBA1 and HBA2 genes on chromosome 16, which encode alpha-globin chains. There are normally four alpha-globin genes; severity depends on how many are deleted. Silent carrier (1 gene deleted) is asymptomatic; alpha-thalassemia trait (2 genes deleted) causes mild microcytosis; HbH disease (3 genes deleted) causes moderate hemolytic anemia; and Hb Bart's hydrops fetalis (all 4 genes deleted) is fatal without in utero intervention. Beta-thalassemia is the predominant form affecting patients from the Mediterranean, Middle East, and South Asia; alpha-thalassemia has its highest burden in Southeast Asia, China, and sub-Saharan Africa.

Transfusion-dependent thalassemia (TDT) means the patient requires regular red blood cell transfusions — typically every 2–4 weeks — to maintain hemoglobin above a target level (usually 9–10.5 g/dL pre-transfusion) that prevents the complications of severe chronic anemia. Without transfusions, TDT patients develop profound anemia, massive splenomegaly, bone marrow expansion causing skeletal deformities, growth failure, and early death. With regular transfusions, growth and development are maintained — but transfusion-related iron overload becomes the primary challenge, requiring lifelong iron chelation therapy to prevent organ damage. TDT is the clinical threshold at which curative therapies — allogeneic stem cell transplantation and gene therapy — are most clearly indicated, as the burden of chronic transfusion dependency and its complications justifies the risks of curative approaches.

Gene therapy for thalassemia aims to correct the underlying hemoglobin defect by modifying the patient's own hematopoietic stem cells. Two approaches are approved: Casgevy (exagamglogene autotemcel) uses CRISPR/Cas9 gene editing to reactivate fetal hemoglobin production by disrupting the BCL11A gene, enabling the patient's cells to produce HbF instead of defective adult hemoglobin. Zynteglo (betibeglogene autotemcel) uses a lentiviral vector to add a functional beta-globin gene to the patient's stem cells. Both require: the patient to have confirmed TDT (requiring regular transfusions); to be ≥12 years old; to have adequate organ function; and to undergo stem cell mobilization, collection, ex vivo modification, myeloablative conditioning, and reinfusion — a process taking several months at a certified gene therapy center. In trials, the majority of treated patients achieved transfusion independence. Gene therapy is a one-time treatment but is not without risks — myeloablative conditioning is intensive and may affect fertility. Not all TDT patients are eligible; specialist assessment at a certified gene therapy center is required.

Yes — allogeneic stem cell transplantation (allo-SCT) remains a critical and complementary curative option alongside gene therapy. Allo-SCT replaces the patient's defective blood-forming system with donor stem cells that produce normal hemoglobin. For patients with an HLA-identical matched sibling donor (approximately 25–30% of TDT patients), allo-SCT remains the preferred curative approach — particularly in young children where transplant outcomes are excellent (thalassemia-free survival >90% at specialist centers) and where gene therapy has not yet been approved for younger age groups. Gene therapy avoids donor-related risks (GVHD, graft rejection) and is suitable for patients without a matched donor — but its high cost and complex logistics make it inaccessible for many families globally, particularly in endemic regions. Haploidentical transplantation has expanded access for the majority of patients without a matched sibling. The choice between allo-SCT and gene therapy depends on donor availability, patient age, iron burden, and access to certified centers for each modality.

Iron chelation therapy is the use of drugs that bind to excess iron in the body and promote its excretion through urine or stool — preventing the toxic accumulation of iron in the heart, liver, endocrine glands, and other organs. In TDT, each unit of transfused blood delivers approximately 200–250 mg of iron that the body cannot excrete normally, and iron also accumulates from increased intestinal absorption driven by ineffective erythropoiesis in NTDT. Without chelation, iron progressively deposits in the myocardium (causing fatal arrhythmias and heart failure), liver (causing cirrhosis), pancreas (causing diabetes), thyroid (causing hypothyroidism), and gonads (causing infertility). Three approved chelators are available: deferoxamine (SC/IV infusion, most experience), deferasirox (once-daily oral, most widely used globally), and deferiprone (thrice-daily oral, best cardiac iron removal). Choice and combination of chelators is tailored to the dominant site of iron overload assessed by MRI T2*. Adherence to chelation is the single most modifiable determinant of long-term outcomes in TDT patients not yet cured by transplant or gene therapy.

When both parents are thalassemia carriers, each pregnancy has a 25% chance of producing a child with thalassemia major, a 50% chance of another carrier, and a 25% chance of a completely unaffected child. Several reproductive options exist: preimplantation genetic diagnosis (PGD) combined with in vitro fertilization (IVF) tests embryos created in the laboratory for the thalassemia gene before implantation, enabling selection and transfer of unaffected embryos; prenatal diagnosis by chorionic villus sampling (CVS) at 10–13 weeks or amniocentesis at 15–18 weeks identifies the fetal genotype, giving parents information for decision-making during pregnancy; and in some centers, preconception genetic testing of eggs before fertilization is available. These options require confirmed genotyping of both parents before they can be offered. All carrier couples planning a pregnancy should receive genetic counseling from a specialist thalassemia center or clinical genetics service to fully understand their options, their risks, and the implications of each approach.

Luspatercept (Reblozyl) is an erythroid maturation agent — not a gene therapy — that works by trapping TGF-β superfamily ligands that normally block the final stages of red blood cell maturation in thalassemia bone marrow. By reducing this signaling, luspatercept allows more red blood cells to complete maturation, modestly improving hemoglobin and reducing transfusion frequency. It is approved for adults with TDT requiring ≥4 transfusions per 8 weeks, given as a subcutaneous injection every 3 weeks. Luspatercept reduces transfusion burden by at least one-third in approximately 21% of treated patients; a smaller minority achieve transfusion independence. It does not cure thalassemia, does not reduce iron overload, and does not modify the underlying genetic defect. Gene therapy, by contrast, is a one-time treatment that can eliminate transfusion dependence in the majority of treated patients by correcting the hemoglobin defect at the level of the hematopoietic stem cell. Luspatercept is an important adjunct for patients not yet eligible for or awaiting gene therapy or transplant.

Thalassemia has one of its highest global disease burdens in India and South Asia. An estimated 40–50 million people in India alone are carriers of beta-thalassemia, representing approximately 3–4% of the Indian population — with carrier rates significantly higher in specific ethnic communities (Gujaratis, Sindhis, Punjabis, Bengalis, Baniyas) where rates of 5–15% are reported. Approximately 7,000–10,000 children are born with beta-thalassemia major in India each year. HbE/beta-thalassemia is the dominant severe hemoglobin disorder in Northeast India and neighboring Bangladesh. The disease burden is immense and universal carrier screening programs remain incomplete in most Indian states, meaning many affected children are born to couples who did not know they were both carriers. Access to optimal transfusion programs, iron chelation therapy, and curative transplantation varies widely across regions. The emergence of gene therapy centers in India represents a significant step toward making curative therapy accessible to this large and underserved population.

Yes. CancerFax supports thalassemia patients and families by reviewing genotype reports, hemoglobin electrophoresis results, ferritin levels, MRI T2* results, and transfusion history to confirm disease classification and assess eligibility for curative therapy; coordinating specialist hematology and thalassemia center second opinions for gene therapy (Casgevy, Zynteglo) and stem cell transplant eligibility assessment; facilitating connections to certified gene therapy centers and bone marrow transplant programs — including specialist centers in India, China, and globally where expert thalassemia care and curative therapy access are concentrated; and helping patients navigate clinical trial options for novel therapies including mitapivat, TMPRSS6 inhibitors, and next-generation gene editing approaches. Contact CancerFax to discuss your specific thalassemia subtype, genotype, current management, and goals for curative therapy access.